Table 1_Integrating molecular targeting and immune modulation in triple-negative breast cancer: from mechanistic insights to therapeutic innovation.xlsx Por Yueren Fan (22687577)

Assuntos:

Figure S5 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors Por Martina S.J. McDermott (15206951)

Assuntos:

Supplemental Tables 1 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors Por Martina S.J. McDermott (15206951)

Assuntos:

Figure S7 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors Por Martina S.J. McDermott (15206951)

Assuntos:

Figure S6 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors Por Martina S.J. McDermott (15206951)

Assuntos:

Figure S1 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors Por Martina S.J. McDermott (15206951)

Assuntos:

Figure S8 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors Por Martina S.J. McDermott (15206951)

Assuntos:

Figure S3 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors Por Martina S.J. McDermott (15206951)

Assuntos:

Figure S4 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors Por Martina S.J. McDermott (15206951)

Assuntos:

Figure S2 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors Por Martina S.J. McDermott (15206951)

Assuntos:

Supplementary Tables from Therapy-Induced Senescence Enhances the Efficacy of HER2-Targeted Antibody–Drug Conjugates in Breast Cancer Por Santiago Duro-Sánchez (14959182)

Assuntos:

Figures S1-S2 from Preclinical and Clinical Efficacy of Trastuzumab Deruxtecan in Breast Cancer Brain Metastases Por Sheheryar Kabraji (15050565)

Assuntos:

Table S1 from Breast Cancer Mutations <i>HER2^V777L</i> and <i>PIK3CA^H1047R</i> Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistan... Por Xiaoqing Cheng (16918496)

Assuntos:

Table S5 from Breast Cancer Mutations <i>HER2^V777L</i> and <i>PIK3CA^H1047R</i> Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistan... Por Xiaoqing Cheng (16918496)

Assuntos:

Table S6 from Breast Cancer Mutations <i>HER2^V777L</i> and <i>PIK3CA^H1047R</i> Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistan... Por Xiaoqing Cheng (16918496)

Assuntos:

Table S2 from Breast Cancer Mutations <i>HER2^V777L</i> and <i>PIK3CA^H1047R</i> Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistan... Por Xiaoqing Cheng (16918496)

Assuntos:

Table S3 from Breast Cancer Mutations <i>HER2^V777L</i> and <i>PIK3CA^H1047R</i> Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistan... Por Xiaoqing Cheng (16918496)

Assuntos:

Table S4 from Breast Cancer Mutations <i>HER2^V777L</i> and <i>PIK3CA^H1047R</i> Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistan... Por Xiaoqing Cheng (16918496)

Assuntos:

Supplementary Table S3 from Targeting CD44 Variant 5 with an Antibody–Drug Conjugate Is an Effective Therapeutic Strategy for Intrahepatic Cholangiocarcinoma Por Yuncheng Bei (16546095)

Assuntos:

Supplementary Table S1 from Targeting CD44 Variant 5 with an Antibody–Drug Conjugate Is an Effective Therapeutic Strategy for Intrahepatic Cholangiocarcinoma Por Yuncheng Bei (16546095)

Assuntos: